- Zacks Small Cap Research•5 months agoARLZ: A Strong Management Team and Plenty of Capital Makes Aralez a Top Specialty Pharmaceutical Pick…
On February 5, 2015, Aralez Pharmaceuticals Inc. (ARLZ) announced that the planned merger between Pozen, Inc. and Tribute Pharmaceuticals Canada, Inc. was complete following approval by the shareholders of each company. The strategy behind Aralez is that the company will become a cardiovascular focused specialty pharmaceutical company with support from a pain-focused franchise. As a reminder, in conjunction with the completion of the merger, a group of leading healthcare investors, led by Deerfield Management, has committed up to $350 million in capital for Aralez to fund the anticipated commercial launch of YOSPRALA® and for “future acquisitions”.
We keep the tough going with 2,300 convenient locations, 6,500 helpful employees & a 97% customer satisfaction rating. Talk about strength in numbers.
- Insider Monkey•6 months agoBillionaire Steven Cohen Reveals Two New Stock Picks, While Roberto Mignone Boosts Chimerix Inc. (CMRX) Stake
The hedge fund industry as a whole did not perform particularly well in 2015, but there were a few investment vehicles that managed to greatly outperform the broader market. Steven Cohen’s family office Point72 Asset Management was one of those, as it gained almost 16% last year, while the S&P 500 Index closed the year in negative […]
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|52wk Range||undefined - undefined|
|Day's Range||N/A - N/A|
|Avg Vol (3m)||N/A|